LLY

757.36

+3.2%↑

JNJ

151.29

+1.18%↑

UNH

291.24

+6.59%↑

ABBV

183.96

+1.27%↑

NVO

64.34

-2.56%↓

LLY

757.36

+3.2%↑

JNJ

151.29

+1.18%↑

UNH

291.24

+6.59%↑

ABBV

183.96

+1.27%↑

NVO

64.34

-2.56%↓

LLY

757.36

+3.2%↑

JNJ

151.29

+1.18%↑

UNH

291.24

+6.59%↑

ABBV

183.96

+1.27%↑

NVO

64.34

-2.56%↓

LLY

757.36

+3.2%↑

JNJ

151.29

+1.18%↑

UNH

291.24

+6.59%↑

ABBV

183.96

+1.27%↑

NVO

64.34

-2.56%↓

LLY

757.36

+3.2%↑

JNJ

151.29

+1.18%↑

UNH

291.24

+6.59%↑

ABBV

183.96

+1.27%↑

NVO

64.34

-2.56%↓

Search

Novartis AG

Aperta

108.67 1.07

Panoramica

Variazione del prezzo dell'azione

24h

Corrente

Minimo

107.56

Massimo

108.99

Metriche Chiave

By Trading Economics

Entrata

786M

3.6B

Vendite

62M

14B

P/E

Media del settore

17.077

56.602

EPS

2.28

Rendimento da dividendi

3.67

Margine di Profitto

26.476

Dipendenti

75,883

EBITDA

643M

5.8B

Raccomandazioni

By TipRanks

Raccomandazioni

Neutrale

Previsioni per 12 mesi

+1.91% upside

Dividendi

By Dow Jones

Rendimento da dividendi

Media del settore

3.67%

2.45%

Statistiche di mercato

By TradingEconomics

Capitalizzazione di Mercato

-765M

217B

Apertura precedente

107.6

Chiusura precedente

108.67

Punteggio Tecnico

By Trading Central

Fiducia

Bearish Evidence

Novartis AG Grafico

Le prestazioni passate non sono un indicatore affidabile dei risultati futuri.

Notizie correlate

12 mag 2025, 09:36 UTC

I principali Market Mover

Global Pharma Stocks Fall as Trump Plans to Cut Drug Prices

30 apr 2025, 16:35 UTC

I principali Market Mover
Acquisizioni, Fusioni, Takeovers

Regulus Shares Surge on $1.7 Billion Acquisition by Novartis

30 apr 2025, 11:55 UTC

Acquisizioni, Fusioni, Takeovers

Novartis to Acquire MicroRNA-Technology Specialist Regulus for Up to $1.7 Billion

30 apr 2025, 11:54 UTC

Acquisizioni, Fusioni, Takeovers

Novartis to Acquire Regulus in $1.7 Billion Deal

29 apr 2025, 07:09 UTC

Utili

Novartis Lifts Guidance After Profit, Sales Top Views -- Update

29 apr 2025, 05:36 UTC

Utili

Novartis Lifts Guidance After Profit, Sales Top Views

12 mag 2025, 22:14 UTC

Notizie principali

Drugmakers Spared Worst-Case Drug Pricing Scenario for Now -- 2nd Update

12 mag 2025, 18:45 UTC

Notizie principali

Drugmakers Spared Worst-Case Drug Pricing Scenario for Now -- Update

30 apr 2025, 11:40 UTC

Acquisizioni, Fusioni, Takeovers

Novartis to Acquire MicroRNA-Technology Specialist Regulus for Up to $1.7 Bln

30 apr 2025, 11:39 UTC

Acquisizioni, Fusioni, Takeovers

Novartis to Acquire Regulus in $1.7B Deal

30 apr 2025, 11:16 UTC

Acquisizioni, Fusioni, Takeovers

Novartis: Transaction Is Expected to Close in Second Half of 2025

30 apr 2025, 11:15 UTC

Acquisizioni, Fusioni, Takeovers

Novartis: Regulus Therapeutics Is U.S. Biotech Focused on microRNA Therapeutics

30 apr 2025, 11:14 UTC

Acquisizioni, Fusioni, Takeovers

Novartis: Transaction Includes USD0.8B Upfront Payment, Potential Additional USD 0.9B Payment

30 apr 2025, 11:13 UTC

Acquisizioni, Fusioni, Takeovers

Novartis to Buy Regulus Therapeutics

29 apr 2025, 12:34 UTC

Discorsi di Mercato
Utili

Novartis Solid Result Shifts Investor Focus to 2H -- Market Talk

29 apr 2025, 11:54 UTC

Discorsi di Mercato
Utili

Correction to Novartis Market Talk

29 apr 2025, 11:47 UTC

Discorsi di Mercato
Utili

Novartis Guidance Lift Seems Positive Signal for Investors -- Market Talk

29 apr 2025, 10:42 UTC

Discorsi di Mercato
Utili

Novartis Surprises With Another Beat & Raise -- Market Talk

29 apr 2025, 10:16 UTC

Discorsi di Mercato
Utili

Novartis's Guidance Lift Reflects Strong Sales -- Market Talk

29 apr 2025, 05:06 UTC

Utili

Novartis Had Seen Core Operating Profit to Grow at High Single to Low Double-Digit in 2025 at Constant Currencies

29 apr 2025, 05:06 UTC

Utili

Novartis Expects Core Operating Profit to Grow Low Double-Digit in 2025 at Constant Currencies

29 apr 2025, 05:05 UTC

Utili

Novartis Had Seen Sales Grow Mid- to High-Single Digit in 2025 at Constant Currencies

29 apr 2025, 05:04 UTC

Utili

Novartis Expects Sales to Grow High Single Digit in 2025 at Constant Currencies

29 apr 2025, 05:02 UTC

Utili

Novartis Raises 2025 View

29 apr 2025, 05:02 UTC

Utili

Analysts Had Seen Novartis 1Q Rev $13.00B

29 apr 2025, 05:02 UTC

Utili

Novartis 1Q Rev $13.23B

29 apr 2025, 05:01 UTC

Utili

Analysts Had Seen Novartis 1Q Core Operating Profit EUR5.22B

29 apr 2025, 05:01 UTC

Utili

Novartis 1Q Core Operating Profit EUR5.575B

29 apr 2025, 05:00 UTC

Utili

Novartis AG 1Q Adj EPS $2.28

29 apr 2025, 05:00 UTC

Utili

Novartis AG 1Q EPS $1.83

Confronto tra pari

Modifica del prezzo

Novartis AG Previsione

Obiettivo di Prezzo

By TipRanks

1.91% in crescita

Previsioni per 12 mesi

Media 107 USD  1.91%

Alto 116 USD

Basso 88 USD

Basato su 5 analisti di Wall Street che offrono Obiettivi di Prezzo a 12 mesi per Novartis AG - Dist negli ultimi 3 mesi.

Consenso sulla valutazione

By TipRanks

Neutrale

5 ratings

2

Acquista

2

Mantieni

1

Vendi

Punteggio Tecnico

By Trading Central

N/A / 112.63Supporto e resistenza

A breve termine

Bearish Evidence

A termine intermedio

Weak Bullish Evidence

A lungo termine

Strong Bullish Evidence

Notizie finanziarie

Spese di vendita e di amministrazione

Spese operative

Utile prima delle imposte

Vendite

Costo delle vendite

Utile lordo sulle vendite

Interessi passivi sul debito

EBITDA

Utile operativo

$

Chi Siamo Novartis AG

Novartis AG engages in the research, development, manufacture, and marketing of healthcare products in Switzerland and internationally. The company offers prescription medicines for patients and physicians. The company also provides Pluvicto, lutetium Lu 177 vipivotide tetraxetan, indicated for the treatment of adult patients with prostate-specific membrane antigen (PSMA)-positive metastatic castration-resistant prostate cancer; and Lutathera, lutetium Lu 177 dotatate, a prescription medicine used to treat adults and children aged 12 years and older with gastroenteropancreatic neuroendocrine tumors. It focuses on therapeutic areas, such as cardiovascular, renal and metabolic, immunology, neuroscience, and oncology, as well as ophthalmology and hematology. The company has a license and collaboration agreement with Alnylam Pharmaceuticals to develop, manufacture, and commercialize inclisiran, a therapy to reduce LDL cholesterol; and Dawn Health for the development and commercialization of Ekiva, a digital solution designed for people living with Paroxysmal Nocturnal Hemoglobinuria. It also has a research collaboration and license agreement with Schrödinger, Inc. to identify and develop various therapeutic candidates; and a strategic collaboration with Vyriad, Inc. for the discovery and development for vivo chimeric antigen receptor T-cell therapies. The company was incorporated in 1996 and is headquartered in Basel, Switzerland.